Bicizumab manufacturers and official information

Bimekizumab is a new type of humanized IgG1 monoclonal antibody, developed and produced by UCB Pharma, a well-known Belgian pharmaceutical company. UCB is a multinational biopharmaceutical company focused on neurological and immune diseases, headquartered in Brussels, Belgium. It has long been committed to developing innovative therapies to meet unmet clinical needs.

Bicizumab, as the company's important breakthrough product in the field of immunotherapy, mainly targets and simultaneously inhibits inflammatory factorsIL-17A and IL-17F, showing better anti-inflammatory effects than single-target drugs. The drug was initially approved for marketing by the European Union in 2021, and was subsequently approved in many countries and regions including the United States, Canada, China, Japan and Australia. Its indications cover moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiological axial spondyloarthritis, and a new indication approved by the FDA in 2024 - hidradenitis suppurativa.

UCB has adopted a strategy of combining scientific data support and patient education in the global promotion of bichizumab. It not only provides detailed prescription information and drug safety guidance, but also improves drug compliance and market acceptance through patient support programs, online educational resources and automatic injection equipment. At present, bichizumab has become one of the most strategically valuable biological agents in UCB's pipeline. It represents an important upgrade from a single-factor to a two-factor regulatory mechanism for IL-17 targeted therapy, and also reflects UCB's strong research and development capabilities at the forefront of immune disease treatment.

Therefore, Bicizumab is developed, manufactured and globally promoted byUCB Pharma. With its dual IL-17 inhibition mechanism, wide range of approved indications and professional support system, it has become an important biological agent for the treatment of modern autoimmune diseases, marking a new stage of IL-17 targeted therapy.

Reference materials:https://www.drugs.com/bimekizumab.html